Novo Nordisk, Eli Lilly fall after Trump comments on weight loss drug pricing
NEW YORK - LifeMD, Inc. (NASDAQ:LFMD), a telehealth provider with impressive 87.57% gross profit margins according to InvestingPro data, announced Tuesday it will offer Ozempic (semaglutide) at $499 per month through its collaboration with Novo Nordisk, expanding access for self-pay and uninsured patients with type 2 diabetes.
The telehealth provider’s platform now integrates with NovoCarePharmachy to provide all FDA-approved dose strengths of Ozempic to eligible patients, including those whose insurance plans don’t cover GLP-1 therapies.
The offering includes virtual consultations with LifeMD’s medical providers, ongoing clinical support, access to diagnostic testing, pharmacy coordination with shipping and tracking, and simplified billing options.
"Our expanded collaboration with Novo Nordisk further advances LifeMD’s mission to make high-quality, branded medications more affordable and accessible for millions of Americans," said Justin Schreiber, Chairman and CEO of LifeMD. The company’s strategic focus appears to be paying off, with revenue growing 37.74% over the last twelve months.
Dave Moore, Executive Vice President of U.S. Operations at Novo Nordisk Inc., noted that approximately 36 million Americans have type 2 diabetes, and this collaboration aims to reach "patients directly where they seek care, offering proven therapies to those who may not have coverage today."
LifeMD’s platform also provides access to Lilly’s prescription obesity treatment Zepbound (tirzepatide) through integration with LillyDirect pharmacy provider, Gifthealth.
The announcement comes as demand for GLP-1 medications continues to grow while many patients face challenges with insurance coverage and availability.
According to the press release statement, these self-pay options complement LifeMD’s insurance-sponsored pharmacy programs and other non-GLP-1 prescriptions for patients seeking more affordable treatment options. With a market capitalization of $305 million and an overall GREAT financial health score according to InvestingPro analysis, LifeMD appears well-positioned to capitalize on the growing telehealth market. InvestingPro analysis suggests the stock is currently undervalued, with additional metrics and insights available to subscribers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.